Share This Page
Drugs in ATC Class G04CB
✉ Email this page to a colleague
Drugs in ATC Class: G04CB - Testosterone-5-alpha reductase inhibitors
| Tradename | Generic Name |
|---|---|
| FINASTERIDE | finasteride |
| PROPECIA | finasteride |
| PROSCAR | finasteride |
| ENTADFI | finasteride; tadalafil |
| FINASTERIDE AND TADALAFIL | finasteride; tadalafil |
| >Tradename | >Generic Name |
Last updated: June 7, 2026
Market dynamics and patent landscape for ATC Class G04CB (testosterone 5‑alpha reductase inhibitors): what patents protect 5α‑reductase inhibitors, when exclusivity ends, and where generic entry risks sit
Executive summary
- ATC G04CB covers 5‑alpha reductase inhibitors (5‑ARIs) used for benign prostatic hyperplasia (BPH) and related androgen-conversion pathways. The key marketed actives are finasteride (5 mg tablet for BPH; and 1 mg for alopecia) and dutasteride (0.5 mg for BPH; and higher-strength trials in some markets historically).
- Patent risk in this class typically clusters in (i) composition-of-matter, (ii) formulation/solid-state, and (iii) method-of-use (BPH dosing regimens), with end-of-exclusivity driven by latest-claimed formulation patents and regulatory data exclusivity rather than the earliest compound filing alone.
- Generic and biosimilar concepts are not directly applicable because these products are small-molecule drugs; the competitive pressure is from ANDAs and design-around of formulation and manufacturing-process claims.
- The dominant commercial pathway is BPH urology (often reimbursed) with high switching costs tied to prescriber inertia and pack-price, so the main entry gating factor is litigation and settlement tied to the Orange Book-listed patents for each NDA.
What drugs are in ATC G04CB (testosterone 5‑alpha reductase inhibitors)?
Answer: The therapeutic anchor in ATC G04CB is 5‑alpha reductase inhibition of type 1 and/or type 2 conversion routes affecting androgen metabolism.
Core marketed actives (global)
- Finasteride
- BPH: commonly marketed as finasteride 5 mg (oral tablet).
- Alopecia: finasteride 1 mg (outside typical BPH-only analyses but still relevant to patent estates that share compositions and processes).
- Dutasteride
- BPH: commonly marketed as dutasteride 0.5 mg (oral capsule/softgel depending on market).
Mechanism and class behavior that impacts IP
- Finasteride selectively inhibits type II 5‑alpha reductase.
- Dutasteride inhibits type I and type II.
- This matters for patent landscapes because many claims differentiate by enzyme selectivity, dose titration, patient subpopulations, and outcome endpoints (prostate volume reduction, symptom score, PSA changes).
How does the patent landscape for finasteride vs dutasteride differ (composition, formulation, and method-of-use)?
Answer: Both have mature compound estates, but durability tends to come from later formulation and use claims, and from region-by-region patent grids rather than a single global “last patent.”
Finasteride: typical claim clusters
- Composition-of-matter: early filings on finasteride itself (generally long expired in major jurisdictions).
- Formulation patents:
- specific tablet compositions,
- excipient systems,
- coating/film properties,
- process improvements (granulation, compression parameters), and
- dissolution profile targets tied to bioavailability.
- Method-of-use patents:
- BPH endpoints with defined dosing and monitoring constructs (e.g., PSA kinetics, prostate volume thresholds),
- specific therapeutic protocols.
Dutasteride: typical claim clusters
- Composition-of-matter: early filings on dutasteride, typically nearing or past base expiration in the largest markets.
- Formulation and dosing:
- capsule/softgel formulation and fill systems,
- dissolution and stability improvements (oxidation control is common for lipophilic actives),
- process claims around manufacturing scale and stability.
- Use claims:
- BPH management protocols and patient stratifications,
- combination therapies sometimes appear as separate IP clusters in the urology field.
Practical implication for patent challenges
- The most common ANDA risk for these products is claim-specific: a generic must either (a) obtain a court/settlement position on the listed patents, or (b) design around formulation and process claims that remain listed or enforceable.
Which patents protect 5‑alpha reductase inhibitors in the US Orange Book (finasteride and dutasteride)?
Answer: US protection is determined by NDA/Orange Book listings that show the patent numbers and expiration dates for each NDA, along with patent-type classifications (e.g., drug substance, drug product, method-of-use). Patent exposure for generic entry is driven by the latest listed patent for the specific listed strength/form.
What “protects” in Orange Book terms
- Drug substance patents: cover the active molecule or key synthetic intermediates.
- Drug product patents: cover formulation, composition of excipients, and manufacturing process.
- Method-of-use patents: cover use claims tied to indications or dosing regimens.
Why this matters for market dynamics
- Generic timelines depend on which listed patents are still enforceable and whether ANDA filers file Paragraph IV challenges to trigger litigation.
(Note: Producing a complete, accurate table of specific Orange Book-listed patent numbers, assignees, and expiration dates requires pulling the latest Orange Book dataset for each relevant NDA and strength. Without those live listings, any named patent grid would risk being incomplete or incorrect.)
When does exclusivity end for finasteride and dutasteride (patent expiration vs regulatory exclusivity)?
Answer: In mature markets, base patent terms typically expired earlier, leaving later-life formulation/use patents and regulatory exclusivity windows (where still relevant) as the practical gating items. For many products in this class, regulatory exclusivity is no longer the binding constraint; patent litigation and remaining listed patents are.
Timing drivers that control “generic reality”
- Patent expiration date for each Orange Book-listed patent.
- PTE/PTE adjustments (where applicable) can shift nominal expiration.
- Laches or enforcement posture in specific cases can change who actually wins barriers.
- 30-month stay behavior after Paragraph IV filing in the US can delay marketing even if ultimate validity is challenged.
Commercial effect
- When litigation clears, entry tends to be rapid, pushing pricing down and shifting share to lowest-net-price distributors and large pharmacy chains.
How many patents cover 5‑alpha reductase inhibitor products, and where are the enforceable claim clusters concentrated?
Answer: In mature small-molecule classes, the highest remaining counts usually sit in drug product (formulation/manufacturing) and method-of-use patents rather than drug substance.
Concentration patterns you should model
- Finasteride:
- fewer remaining drug-substance “life” patents but potential survival in tableting/process and use claims.
- Dutasteride:
- product patents often focus on stability and softgel/capsule manufacturing, and on endpoints tied to BPH management.
Entry gating
- Generic filers tend to focus Paragraph IV arguments on:
- obviousness over older disclosures,
- lack of enablement,
- noninfringement through dissolution/bioequivalence design and process differences.
What generic entry risks exist for finasteride 5 mg and dutasteride 0.5 mg (Paragraph IV, settlements, design-around)?
Answer: The main risks are not “biosimilar-style” but ANDA litigation risk and injunction/market carveouts negotiated through settlements.
Common Paragraph IV outcomes for mature small molecules
- Suit filed after ANDA acceptance; court adjudicates claim validity/infringement.
- Parties may settle to:
- allow earlier launch for generics after a “delayed entry” period,
- compensate brand via payments or shared market structures (structure varies by case),
- agree to entry triggers tied to specific patent carveouts.
Design-around tactics
- Formulation: change excipient system within bioequivalence constraints.
- Manufacturing: change order of operations, equipment specs, or processing parameters.
- Use claims: target labels to avoid the specific method claim language if feasible.
What patent litigation affects the ATC G04CB market (US, EU, UK) and who are the frequent challengers?
Answer: Litigation in this space is typically driven by ANDA filers and generic manufacturers with urology portfolios. The litigation affects:
- launch dates,
- settlement economics,
- and label carveouts.
Where litigation typically shows up
- US: claim-by-claim disputes tied to Orange Book listings.
- Europe/UK: separate national patent litigation and validity challenges, often parallel to US action.
(A complete “who/when/which docket” map requires pulling case-level data tied to each NDA’s listed patents and each jurisdiction, which is not provided in the prompt.)
How do settlement agreements and 30-month stays change market share for 5‑ARIs?
Answer: Settlements and stays primarily affect:
- who launches first,
- how many SKUs arrive initially (strength/form),
- and whether multiple generics launch “at once” after a negotiated date.
Market impact mechanism
- If settlements allow delayed generic launch, branded pricing can remain higher and protect rebate economics longer.
- If courts invalidate key patents, entry clusters and compresses margins faster for all entrants.
What formulations are protected by patents for 5‑alpha reductase inhibitors (solid oral dosage, softgels, dissolution profile)?
Answer: Patents most often target:
- drug product composition (excipients, coating agents, stabilizers),
- solid-state/process parameters (granulation, compression, encapsulation),
- dissolution specifications linked to consistent bioavailability,
- and stability issues (especially for dutasteride).
Why formulations matter commercially
- Even if the active is no longer composition-protected, formulation patents can:
- keep “authorized generic” or first generic entrants out,
- force licensing for manufacturing know-how,
- or require court carveouts to sell.
What manufacturing/IP barriers block generic entry for finasteride and dutasteride?
Answer: For these products, barriers usually arise from:
- ongoing enforceability of drug product patents,
- process claims tied to specific manufacturing steps,
- and evidence of noninfringement being expensive in discovery.
Practical IP friction points
- Dissolution profile demonstration for bioequivalence.
- Control of impurities and stability under storage and shipping.
- Process replication that avoids meeting claim-defined parameters.
How does the G04CB patent estate strength compare across brands (finasteride-originator vs dutasteride-originator)?
Answer: Comparative “strength” is largely a function of:
- how many Orange Book-listed patents remain active,
- their patent types (product vs use),
- and how often those patents face validity attacks.
Competitive read-through
- The market typically has high price elasticity; once one product’s final barrier clears, competitors accelerate entry.
- Brand strategies shift to:
- product lifecycle extensions,
- distribution and rebate intensity,
- and litigation posture.
(Without pulling the live Orange Book and jurisdictional patent registers, a quantified “strength score” across finasteride and dutasteride cannot be stated accurately.)
What is the FDA regulatory status for these 5‑alpha reductase inhibitors (NDA, ANDA counts, approvals, label composition)?
Answer: Regulatory posture in this class is mature. The typical pattern is:
- a small number of original NDAs,
- multiple ANDAs over time once barriers cleared,
- and stable labeling consistent with BPH endpoints.
What to track for market timing
- ANDA filing cadence and any Paragraph IV indicators.
- Approval dates for generic entrants versus the branded product’s exclusivity barriers.
- Any labeling changes that alter infringement analysis for method-of-use patents.
Key Takeaways
- ATC G04CB is a mature small-molecule class dominated by finasteride and dutasteride.
- Real-world “patent protection” durability comes less from base drug-substance patents and more from late-life drug product (formulation/process) and method-of-use claims that remain enforceable in each major jurisdiction.
- Generic entry risk is governed by Orange Book-listed patents, the presence of Paragraph IV challenges, and settlement-driven entry dates, not by biosimilar-style mechanisms.
- Competitive pressure increases sharply once key formulation or use patents are cleared, typically leading to rapid pricing normalization.
FAQs
- Which patent types are most likely to delay ANDA approval for finasteride or dutasteride in the US?
- How do formulation patents for dutasteride softgel/capsule compositions change generic manufacturing timelines?
- What court outcomes most often lead to early generic launch for 5‑alpha reductase inhibitors?
- How do label carveouts around method-of-use claims affect infringement risk for generic entrants?
- What commercial metrics best indicate that the final patent barrier for a 5‑ARI has cleared (price erosion vs share shift)?
References
- (No sources were provided or retrievable from the prompt text.)
More… ↓
